Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Celgene and Agios to collaborate on cancer research

Celgene and Agios to collaborate on cancer research

16th April 2010

Celgene is to ally with Agios Pharmaceuticals in a new partnership dedicated to the development of drugs based on cancer metabolism.

The agreement will see the companies utilise Agios’ new cancer metabolism research platform to create therapies which combat the disease by targeting enzymes that are key to cancer proliferation.

Agios will take the lead in the discovery and early development of these treatments, while Celgene has been granted the option to licence and commercialise clinical candidates beyond phase I testing.

Under the terms of the deal, Agios has been provided with a $130 million (84.3 million pounds) upfront payment, with a potential $120 million set to be paid depending on the achievement of developmental and commercial milestones.

Dr Thomas Daniel, president of research for Celgene, said: “We believe the strategic alliance with Agios can expand our deep and diverse pipeline of innovative programmes focused on changing treatment paradigms in serious and debilitating diseases.”

According to Celgene’s most recent financial report, the company experienced a year-on-year increase in revenue in 2009, driven by the success of treatments such as Revlimid and Vidaza.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.